Andrew C. Sher
Baylor College of Medicine
18 Papers
31 Citations
Andrew C. Sher is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Medicine & PET-CT. The author has an hindex of 3, co-authored 18 publications. Previous affiliations of Andrew C. Sher include Boston Children's Hospital.
Chat about Author
Papers
PET/MR in the Assessment of Pediatric Histiocytoses: A Comparison to PET/CT.
Andrew C. Sher,Robert C. Orth,Kenneth L. McClain,Carl E. Allen,Shireen E. Hayatghaibi,Victor J. Seghers +5 more
TL;DR: PET/MR demonstrates comparable image quality and lesion detection toPET/CT while maintaining strongly correlated quantitative performance, and represents an appealing alternative to PET/CT in the care of children with histiocytic disorders.
24
Response to the COVID-19 Pandemic: Practical Guide to Rapidly Deploying Home Workstations to Guarantee Radiology Services During Quarantine, Social Distancing, and Stay Home Orders.
Marla B. K. Sammer,Marla B. K. Sammer,Andrew C. Sher,Andrew C. Sher,Thierry A.G.M. Huisman,Thierry A.G.M. Huisman,Victor J. Seghers,Victor J. Seghers +7 more
TL;DR: An experience in the rapid deployment of home workstations that illustrates a creative solution that transcended typical administrative barriers in response to the global coronavirus disease pandemic is shared.
23
Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia
Samara L. Potter,Rajkumar Venkatramani,Scott E. Wenderfer,Brett H. Graham,Sanjeev A. Vasudevan,Sanjeev A. Vasudevan,Andrew C. Sher,Hao Wu,Hao Wu,David A. Wheeler,Yaping Yang,Christine M. Eng,Richard A. Gibbs,Angshumoy Roy,Sharon E. Plon,D. Williams Parsons +15 more
TL;DR: Clinical whole exome sequencing of blood and tumor samples confirmed the diagnosis of MMA and revealed two somatic inactivating mutations in TSC2, suggesting the potential consideration of an mTOR inhibitor in the event of tumor recurrence.
Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children.
Jennifer Foster,Andrew C. Sher,Victor J. Seghers,Jay Poston,Donald Wells,Ebrahim S Delpassand,Samara L. Potter,Priya Mahajan,Rajkumar Venkatramani +8 more
TL;DR: In this article, the authors reported their experience using 177 Lu-DOTATATE to treat two pediatric patients with metastatic neuroendocrine tumors (NETs) of the pancreas and midgut.
9
Prospective cost implications with a clinical decision support system for pediatric emergency head computed tomography
Shireen E. Hayatghaibi,Shireen E. Hayatghaibi,Marla B. K. Sammer,Marla B. K. Sammer,Varsha Varghese,Victor J. Seghers,Victor J. Seghers,Andrew C. Sher,Andrew C. Sher +8 more
TL;DR: In this article, a clinical decision support tool for imaging, CareSelect (National Decision Support Co., Madison, WI), was integrated in silent mode into the electronic health record from September 2018 through August 2019, and the percentage of low-utility non-contrast head computed tomography (CT) examinations on emergency patients and calculated the prospective cost implications of providing low-value imaging using time-driven activity-based costing at an academic quaternary pediatric hospital.